Cargando…

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review

PURPOSE: The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of zanbrutinib are described. SUMMARY: Mantle cell lymphoma (MCL) is a mature B-cell lymphoma that is typically associated with unfavorable outcomes, and virtually all patients with MCL have refractory or re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsuhebany, Nada, Pan, Congshan, Holovac, Eileen, Do, Brian, McBride, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683511/ https://www.ncbi.nlm.nih.gov/pubmed/38034984 http://dx.doi.org/10.2147/BLCTT.S426588

Ejemplares similares

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
Publicado: (2020)

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
por: Zhou, Keshu, et al.
Publicado: (2021)

Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 Ruling
por: Alsuhebany, Nada, et al.
Publicado: (2022)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
por: Song, Yuqin, et al.
Publicado: (2022)

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
por: Song, Yuqin, et al.
Publicado: (2023)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
por: Qu, Chang-Ju, et al.
Publicado: (2023)

Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis
por: Song, Yuqin, et al.
Publicado: (2023)

Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib
por: Cheng, Qiansong, et al.
Publicado: (2021)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States
por: Alrawashdh, Neda, et al.
Publicado: (2022)

Management of mantle cell lymphoma in the elderly patient
por: Doorduijn, Jeanette K, et al.
Publicado: (2013)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

P1242: ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
por: Zhang, Y., et al.
Publicado: (2022)

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib
por: Zhang, Xiao, et al.
Publicado: (2022)

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
por: Wang, Liang, et al.
Publicado: (2021)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
por: Yang, Haiyan, et al.
Publicado: (2022)

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
por: Wang, Kun, et al.
Publicado: (2021)

Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy
por: Nguyen, Thi H. O., et al.
Publicado: (2023)

Mantle cell lymphoma and its management: where are we now?
por: Ladha, Abdullah, et al.
Publicado: (2019)

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
por: Opat, Stephen, et al.
Publicado: (2023)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

Primary gastric mantle cell lymphoma
por: Petranovic, Duska, et al.
Publicado: (2012)

Mantle cell lymphoma with skin involvement
por: Kalińska-Bienias, Agnieszka, et al.
Publicado: (2015)

Esophageal location of mantle cell lymphoma
por: Michopoulos, Spyros
Publicado: (2016)

Tracheobronchial involvement of mantle cell lymphoma
por: Tong, Lin, et al.
Publicado: (2018)

Mantle Cell Lymphoma Case Report
por: Podzolkov, V.I., et al.
Publicado: (2018)

Educational Case: Mantle Cell Lymphoma
por: Mai, Brenda, et al.
Publicado: (2020)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7uv3mifmrrgeeb1c46fm95126e